Amplification of MYC has been described in many types of tumor, including breast, cervical and colon cancers, as well as in squamous cell carcinomas of the head and neck, myeloma, non-Hodgkin lymphoma, gastric adenocarcinomas and ovarian cancer. MYC is the most frequently amplified oncogene and the elevated expression of its gene product correlates with tumor aggression and poor clinical outcome.
The proto-oncogene MYC, located at 8q24.1, encodes a nuclear phosphoprotein transcription factor which has an integral role in a variety of cellular processes, such as cell cycle progression, proliferation, metabolism, adhesion, differentiation, and apoptosis.
Clinical Applications
- Solid Tumors (Solid Tumors)